APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurotransmitter Inhibitor Peptides

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neurotransmitter Inhibitor Peptides Market Outlook and Growth Opportunities 2026

13 August 2026210 pages

Choose your research edition.

Industry ResearchNeurotransmitter Inhibitor Peptides Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurotransmitter Inhibitor Peptides Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Neurotransmitter Inhibitor Peptides Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurotransmitter Inhibitor Peptides Market Outlook and Growth Opportunities 2026210 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurotransmitter Inhibitor Peptides Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

The global Neurotransmitter Inhibitor Peptides market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neurotransmitter Inhibitor Peptides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurotransmitter Inhibitor Peptides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurotransmitter Inhibitor Peptides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neurotransmitter Inhibitor Peptides market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neurotransmitter Inhibitor Peptides market include Lubrizol (Lipotec), dsm-firmenich, LipoTrue, Spec-Chem Industry, GenScript, Active Peptide Company, Uniproma Chemical, BOC Sciences (AAPEP) and GfN Selco, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neurotransmitter Inhibitor Peptides market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurotransmitter Inhibitor Peptides and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurotransmitter Inhibitor Peptides sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neurotransmitter Inhibitor Peptides market size, projected growth trends, production technologies, key applications, and end-use industries.

Neurotransmitter Inhibitor Peptides Segment by Company

Lubrizol (Lipotec)

dsm-firmenich

LipoTrue

Spec-Chem Industry

GenScript

Active Peptide Company

Uniproma Chemical

BOC Sciences (AAPEP)

GfN Selco

COSROMA

Gene-Biocon

ChinaPeptides (QYAOBIO)

Pengting Peptide

RS Synthesis

Shenzhen JYMed Technology Co., Ltd.

Nanjing Peptide Biotech

AAPPTec

Tianji Bio-pharmaceutical

Zhejiang Peptites Biotech

Guangzhou Tongjun Pharmaceutical Technology

Hantide Biomedical Group

Hangzhou Go Top Biotech

Neurotransmitter Inhibitor Peptides Segment by Type

SNARE-Complex Modulating Peptides

SNAP-25 Mimicking Peptides

Others

Neurotransmitter Inhibitor Peptides Segment by Application

Eye Care Products

Facial Serums

Face Creams and Lotions

Other

Neurotransmitter Inhibitor Peptides Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neurotransmitter Inhibitor Peptides status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neurotransmitter Inhibitor Peptides market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neurotransmitter Inhibitor Peptides significant trends, drivers, influence factors in global and regions.

6. To analyze Neurotransmitter Inhibitor Peptides competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurotransmitter Inhibitor Peptides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurotransmitter Inhibitor Peptides and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurotransmitter Inhibitor Peptides.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neurotransmitter Inhibitor Peptides market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurotransmitter Inhibitor Peptides industry.

Chapter 3: Detailed analysis of Neurotransmitter Inhibitor Peptides manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neurotransmitter Inhibitor Peptides in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neurotransmitter Inhibitor Peptides in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neurotransmitter Inhibitor Peptides Industry Trends Table 2. Neurotransmitter Inhibitor Peptides Industry Drivers Table 3. Neurotransmitter Inhibitor Peptides Industry Opportunities and Challenges Table 4. Neurotransmitter Inhibitor Peptides Industry Restraints Table 5. Global Neurotransmitter Inhibitor Peptides Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neurotransmitter Inhibitor Peptides Revenue Share by Company (2021-2026) Table 7. Global Neurotransmitter Inhibitor Peptides Sales Volume by Company (t) & (2021-2026) Table 8. Global Neurotransmitter Inhibitor Peptides Sales Volume Share by Company (2021-2026) Table 9. Global Neurotransmitter Inhibitor Peptides Average Price (USD/t) of Company (2021-2026) Table 10. Global Neurotransmitter Inhibitor Peptides Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neurotransmitter Inhibitor Peptides Key Company Manufacturing Base & Headquarters Table 12. Global Neurotransmitter Inhibitor Peptides Company, Product Type & Application Table 13. Global Neurotransmitter Inhibitor Peptides Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neurotransmitter Inhibitor Peptides by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of SNARE-Complex Modulating Peptides Table 18. Significant Companies of SNAP-25 Mimicking Peptides Table 19. Significant Companies of Others Table 20. Global Neurotransmitter Inhibitor Peptides Sales Volume by Type 2021 VS 2025 VS 2032 (t) Table 21. Global Neurotransmitter Inhibitor Peptides Sales Volume by Type (2021-2026) & (t) Table 22. Global Neurotransmitter Inhibitor Peptides Sales Volume by Type (2027-2032) & (t) Table 23. Global Neurotransmitter Inhibitor Peptides Sales Volume Share by Type (2021-2026) Table 24. Global Neurotransmitter Inhibitor Peptides Sales Volume Share by Type (2027-2032) Table 25. Global Neurotransmitter Inhibitor Peptides Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Neurotransmitter Inhibitor Peptides Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Neurotransmitter Inhibitor Peptides Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Neurotransmitter Inhibitor Peptides Sales Value Share by Type (2021-2026) Table 29. Global Neurotransmitter Inhibitor Peptides Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Eye Care Products Table 31. Significant Companies of Facial Serums Table 32. Significant Companies of Face Creams and Lotions Table 33. Significant Companies of Other Table 34. Global Neurotransmitter Inhibitor Peptides Sales Volume by Application 2021 VS 2025 VS 2032 (t) Table 35. Global Neurotransmitter Inhibitor Peptides Sales Volume by Application (2021-2026) & (t) Table 36. Global Neurotransmitter Inhibitor Peptides Sales Volume by Application (2027-2032) & (t) Table 37. Global Neurotransmitter Inhibitor Peptides Sales Volume Share by Application (2021-2026) Table 38. Global Neurotransmitter Inhibitor Peptides Sales Volume Share by Application (2027-2032) Table 39. Global Neurotransmitter Inhibitor Peptides Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Neurotransmitter Inhibitor Peptides Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Neurotransmitter Inhibitor Peptides Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Neurotransmitter Inhibitor Peptides Sales Value Share by Application (2021-2026) Table 43. Global Neurotransmitter Inhibitor Peptides Sales Value Share by Application (2027-2032) Table 44. Global Neurotransmitter Inhibitor Peptides Sales by Region: 2021 VS 2025 VS 2032 (t) Table 45. Global Neurotransmitter Inhibitor Peptides Sales by Region (2021-2026) & (t) Table 46. Global Neurotransmitter Inhibitor Peptides Sales Market Share by Region (2021-2026) Table 47. Global Neurotransmitter Inhibitor Peptides Sales by Region (2027-2032) & (t) Table 48. Global Neurotransmitter Inhibitor Peptides Sales Market Share by Region (2027-2032) Table 49. Global Neurotransmitter Inhibitor Peptides Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Neurotransmitter Inhibitor Peptides Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Neurotransmitter Inhibitor Peptides Sales Value Share by Region (2021-2026) Table 52. Global Neurotransmitter Inhibitor Peptides Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Neurotransmitter Inhibitor Peptides Sales Value Share by Region (2027-2032) Table 54. Global Neurotransmitter Inhibitor Peptides Market Average Price (USD/t) by Region (2021-2026) Table 55. Global Neurotransmitter Inhibitor Peptides Market Average Price (USD/t) by Region (2027-2032) Table 56. Global Neurotransmitter Inhibitor Peptides Sales by Country: 2021 VS 2025 VS 2032 (t) Table 57. Global Neurotransmitter Inhibitor Peptides Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026) & (t) Table 59. Global Neurotransmitter Inhibitor Peptides Sales Market Share by Country (2021-2026) Table 60. Global Neurotransmitter Inhibitor Peptides Sales by Country (2027-2032) & (t) Table 61. Global Neurotransmitter Inhibitor Peptides Sales Market Share by Country (2027-2032) Table 62. Global Neurotransmitter Inhibitor Peptides Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Neurotransmitter Inhibitor Peptides Sales Value Market Share by Country (2021-2026) Table 64. Global Neurotransmitter Inhibitor Peptides Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Neurotransmitter Inhibitor Peptides Sales Value Market Share by Country (2027-2032) Table 66. Lubrizol (Lipotec) Company Information Table 67. Lubrizol (Lipotec) Business Overview Table 68. Lubrizol (Lipotec) Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 69. Lubrizol (Lipotec) Neurotransmitter Inhibitor Peptides Product Portfolio Table 70. Lubrizol (Lipotec) Recent Development Table 71. dsm-firmenich Company Information Table 72. dsm-firmenich Business Overview Table 73. dsm-firmenich Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 74. dsm-firmenich Neurotransmitter Inhibitor Peptides Product Portfolio Table 75. dsm-firmenich Recent Development Table 76. LipoTrue Company Information Table 77. LipoTrue Business Overview Table 78. LipoTrue Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 79. LipoTrue Neurotransmitter Inhibitor Peptides Product Portfolio Table 80. LipoTrue Recent Development Table 81. Spec-Chem Industry Company Information Table 82. Spec-Chem Industry Business Overview Table 83. Spec-Chem Industry Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 84. Spec-Chem Industry Neurotransmitter Inhibitor Peptides Product Portfolio Table 85. Spec-Chem Industry Recent Development Table 86. GenScript Company Information Table 87. GenScript Business Overview Table 88. GenScript Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 89. GenScript Neurotransmitter Inhibitor Peptides Product Portfolio Table 90. GenScript Recent Development Table 91. Active Peptide Company Company Information Table 92. Active Peptide Company Business Overview Table 93. Active Peptide Company Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 94. Active Peptide Company Neurotransmitter Inhibitor Peptides Product Portfolio Table 95. Active Peptide Company Recent Development Table 96. Uniproma Chemical Company Information Table 97. Uniproma Chemical Business Overview Table 98. Uniproma Chemical Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 99. Uniproma Chemical Neurotransmitter Inhibitor Peptides Product Portfolio Table 100. Uniproma Chemical Recent Development Table 101. BOC Sciences (AAPEP) Company Information Table 102. BOC Sciences (AAPEP) Business Overview Table 103. BOC Sciences (AAPEP) Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 104. BOC Sciences (AAPEP) Neurotransmitter Inhibitor Peptides Product Portfolio Table 105. BOC Sciences (AAPEP) Recent Development Table 106. GfN Selco Company Information Table 107. GfN Selco Business Overview Table 108. GfN Selco Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 109. GfN Selco Neurotransmitter Inhibitor Peptides Product Portfolio Table 110. GfN Selco Recent Development Table 111. COSROMA Company Information Table 112. COSROMA Business Overview Table 113. COSROMA Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 114. COSROMA Neurotransmitter Inhibitor Peptides Product Portfolio Table 115. COSROMA Recent Development Table 116. Gene-Biocon Company Information Table 117. Gene-Biocon Business Overview Table 118. Gene-Biocon Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 119. Gene-Biocon Neurotransmitter Inhibitor Peptides Product Portfolio Table 120. Gene-Biocon Recent Development Table 121. ChinaPeptides (QYAOBIO) Company Information Table 122. ChinaPeptides (QYAOBIO) Business Overview Table 123. ChinaPeptides (QYAOBIO) Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 124. ChinaPeptides (QYAOBIO) Neurotransmitter Inhibitor Peptides Product Portfolio Table 125. ChinaPeptides (QYAOBIO) Recent Development Table 126. Pengting Peptide Company Information Table 127. Pengting Peptide Business Overview Table 128. Pengting Peptide Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 129. Pengting Peptide Neurotransmitter Inhibitor Peptides Product Portfolio Table 130. Pengting Peptide Recent Development Table 131. RS Synthesis Company Information Table 132. RS Synthesis Business Overview Table 133. RS Synthesis Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 134. RS Synthesis Neurotransmitter Inhibitor Peptides Product Portfolio Table 135. RS Synthesis Recent Development Table 136. Shenzhen JYMed Technology Co., Ltd. Company Information Table 137. Shenzhen JYMed Technology Co., Ltd. Business Overview Table 138. Shenzhen JYMed Technology Co., Ltd. Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 139. Shenzhen JYMed Technology Co., Ltd. Neurotransmitter Inhibitor Peptides Product Portfolio Table 140. Shenzhen JYMed Technology Co., Ltd. Recent Development Table 141. Nanjing Peptide Biotech Company Information Table 142. Nanjing Peptide Biotech Business Overview Table 143. Nanjing Peptide Biotech Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 144. Nanjing Peptide Biotech Neurotransmitter Inhibitor Peptides Product Portfolio Table 145. Nanjing Peptide Biotech Recent Development Table 146. AAPPTec Company Information Table 147. AAPPTec Business Overview Table 148. AAPPTec Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 149. AAPPTec Neurotransmitter Inhibitor Peptides Product Portfolio Table 150. AAPPTec Recent Development Table 151. Tianji Bio-pharmaceutical Company Information Table 152. Tianji Bio-pharmaceutical Business Overview Table 153. Tianji Bio-pharmaceutical Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 154. Tianji Bio-pharmaceutical Neurotransmitter Inhibitor Peptides Product Portfolio Table 155. Tianji Bio-pharmaceutical Recent Development Table 156. Zhejiang Peptites Biotech Company Information Table 157. Zhejiang Peptites Biotech Business Overview Table 158. Zhejiang Peptites Biotech Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 159. Zhejiang Peptites Biotech Neurotransmitter Inhibitor Peptides Product Portfolio Table 160. Zhejiang Peptites Biotech Recent Development Table 161. Guangzhou Tongjun Pharmaceutical Technology Company Information Table 162. Guangzhou Tongjun Pharmaceutical Technology Business Overview Table 163. Guangzhou Tongjun Pharmaceutical Technology Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 164. Guangzhou Tongjun Pharmaceutical Technology Neurotransmitter Inhibitor Peptides Product Portfolio Table 165. Guangzhou Tongjun Pharmaceutical Technology Recent Development Table 166. Hantide Biomedical Group Company Information Table 167. Hantide Biomedical Group Business Overview Table 168. Hantide Biomedical Group Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 169. Hantide Biomedical Group Neurotransmitter Inhibitor Peptides Product Portfolio Table 170. Hantide Biomedical Group Recent Development Table 171. Hangzhou Go Top Biotech Company Information Table 172. Hangzhou Go Top Biotech Business Overview Table 173. Hangzhou Go Top Biotech Neurotransmitter Inhibitor Peptides Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 174. Hangzhou Go Top Biotech Neurotransmitter Inhibitor Peptides Product Portfolio Table 175. Hangzhou Go Top Biotech Recent Development Table 176. Key Raw Materials Table 177. Raw Materials Key Suppliers Table 178. Neurotransmitter Inhibitor Peptides Distributors List Table 179. Neurotransmitter Inhibitor Peptides Customers List Table 180. Research Programs/Design for This Report Table 181. Authors List of This Report Table 182. Secondary Sources Table 183. Primary Sources List of Figures Figure 1. Neurotransmitter Inhibitor Peptides Product Image Figure 2. Global Neurotransmitter Inhibitor Peptides Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurotransmitter Inhibitor Peptides Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neurotransmitter Inhibitor Peptides Sales (2021-2032) & (t) Figure 5. Global Neurotransmitter Inhibitor Peptides Sales Average Price (USD/t) & (2021-2032) Figure 6. Global Neurotransmitter Inhibitor Peptides Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. SNARE-Complex Modulating Peptides Image Figure 10. SNAP-25 Mimicking Peptides Image Figure 11. Others Image Figure 12. Global Neurotransmitter Inhibitor Peptides Sales Volume by Type (2021 VS 2025 VS 2032) & (t) Figure 13. Global Neurotransmitter Inhibitor Peptides Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Neurotransmitter Inhibitor Peptides Sales Volume Share by Type (2021-2032) Figure 15. Global Neurotransmitter Inhibitor Peptides Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Neurotransmitter Inhibitor Peptides Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Neurotransmitter Inhibitor Peptides Sales Value Share by Type (2021-2032) Figure 18. Eye Care Products Image Figure 19. Facial Serums Image Figure 20. Face Creams and Lotions Image Figure 21. Other Image Figure 22. Global Neurotransmitter Inhibitor Peptides Sales Volume by Application (2021 VS 2025 VS 2032) & (t) Figure 23. Global Neurotransmitter Inhibitor Peptides Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Neurotransmitter Inhibitor Peptides Sales Volume Share by Application (2021-2032) Figure 25. Global Neurotransmitter Inhibitor Peptides Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Neurotransmitter Inhibitor Peptides Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Neurotransmitter Inhibitor Peptides Sales Value Share by Application (2021-2032) Figure 28. Global Neurotransmitter Inhibitor Peptides Sales by Region: 2021 VS 2025 VS 2032 (t) Figure 29. Global Neurotransmitter Inhibitor Peptides Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Neurotransmitter Inhibitor Peptides Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Neurotransmitter Inhibitor Peptides Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Neurotransmitter Inhibitor Peptides Sales Value (2021-2032) & (US$ Million) Figure 33. North America Neurotransmitter Inhibitor Peptides Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Neurotransmitter Inhibitor Peptides Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Neurotransmitter Inhibitor Peptides Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Neurotransmitter Inhibitor Peptides Sales Value (2021-2032) & (US$ Million) Figure 39. South America Neurotransmitter Inhibitor Peptides Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Neurotransmitter Inhibitor Peptides Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Neurotransmitter Inhibitor Peptides Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Neurotransmitter Inhibitor Peptides Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Neurotransmitter Inhibitor Peptides Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • SNARE-Complex Modulating Peptides
  • SNAP-25 Mimicking Peptides
  • Others
Applications
  • Eye Care Products
  • Facial Serums
  • Face Creams and Lotions
  • Other
Companies covered
  • Lubrizol (Lipotec)
  • dsm-firmenich
  • LipoTrue
  • Spec-Chem Industry
  • GenScript
  • Active Peptide Company
  • Uniproma Chemical
  • BOC Sciences (AAPEP)
  • GfN Selco
  • COSROMA
  • Gene-Biocon
  • ChinaPeptides (QYAOBIO)
  • Pengting Peptide
  • RS Synthesis
  • Shenzhen JYMed Technology Co., Ltd.
  • Nanjing Peptide Biotech
  • AAPPTec
  • Tianji Bio-pharmaceutical
  • Zhejiang Peptites Biotech
  • Guangzhou Tongjun Pharmaceutical Technology
  • Hantide Biomedical Group
  • Hangzhou Go Top Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neurotransmitter Inhibitor Peptides Sales Value (2021-2032)
  4. 1.2.2 Global Neurotransmitter Inhibitor Peptides Sales Volume (2021-2032)
  5. 1.2.3 Global Neurotransmitter Inhibitor Peptides Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neurotransmitter Inhibitor Peptides Market Dynamics
  1. 2.1 Neurotransmitter Inhibitor Peptides Industry Trends
  2. 2.2 Neurotransmitter Inhibitor Peptides Industry Drivers
  3. 2.3 Neurotransmitter Inhibitor Peptides Industry Opportunities and Challenges
  4. 2.4 Neurotransmitter Inhibitor Peptides Industry Restraints
3 Neurotransmitter Inhibitor Peptides Market by Company
  1. 3.1 Global Neurotransmitter Inhibitor Peptides Company Revenue Ranking in 2025
  2. 3.2 Global Neurotransmitter Inhibitor Peptides Revenue by Company (2021-2026)
  3. 3.3 Global Neurotransmitter Inhibitor Peptides Sales Volume by Company (2021-2026)
  4. 3.4 Global Neurotransmitter Inhibitor Peptides Average Price by Company (2021-2026)
  5. 3.5 Global Neurotransmitter Inhibitor Peptides Company Ranking (2024-2026)
  6. 3.6 Global Neurotransmitter Inhibitor Peptides Company Manufacturing Base and Headquarters
  7. 3.7 Global Neurotransmitter Inhibitor Peptides Company Product Type and Application
  8. 3.8 Global Neurotransmitter Inhibitor Peptides Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neurotransmitter Inhibitor Peptides Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neurotransmitter Inhibitor Peptides Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neurotransmitter Inhibitor Peptides Market by Type
  1. 4.1 Neurotransmitter Inhibitor Peptides Type Introduction
  2. 4.1.1 SNARE-Complex Modulating Peptides
  3. 4.1.2 SNAP-25 Mimicking Peptides
  4. 4.1.3 Others
  5. 4.2 Global Neurotransmitter Inhibitor Peptides Sales Volume by Type
  6. 4.2.1 Global Neurotransmitter Inhibitor Peptides Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Neurotransmitter Inhibitor Peptides Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Neurotransmitter Inhibitor Peptides Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Neurotransmitter Inhibitor Peptides Sales Value by Type
  10. 4.3.1 Global Neurotransmitter Inhibitor Peptides Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Neurotransmitter Inhibitor Peptides Sales Value by Type (2021-2032)
  12. 4.3.3 Global Neurotransmitter Inhibitor Peptides Sales Value Share by Type (2021-2032)
5 Neurotransmitter Inhibitor Peptides Market by Application
  1. 5.1 Neurotransmitter Inhibitor Peptides Application Introduction
  2. 5.1.1 Eye Care Products
  3. 5.1.2 Facial Serums
  4. 5.1.3 Face Creams and Lotions
  5. 5.1.4 Other
  6. 5.2 Global Neurotransmitter Inhibitor Peptides Sales Volume by Application
  7. 5.2.1 Global Neurotransmitter Inhibitor Peptides Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Neurotransmitter Inhibitor Peptides Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Neurotransmitter Inhibitor Peptides Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Neurotransmitter Inhibitor Peptides Sales Value by Application
  11. 5.3.1 Global Neurotransmitter Inhibitor Peptides Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Neurotransmitter Inhibitor Peptides Sales Value by Application (2021-2032)
  13. 5.3.3 Global Neurotransmitter Inhibitor Peptides Sales Value Share by Application (2021-2032)
6 Neurotransmitter Inhibitor Peptides Regional Sales and Value Analysis
  1. 6.1 Global Neurotransmitter Inhibitor Peptides Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurotransmitter Inhibitor Peptides Sales by Region (2021-2032)
  3. 6.2.1 Global Neurotransmitter Inhibitor Peptides Sales by Region: 2021-2026
  4. 6.2.2 Global Neurotransmitter Inhibitor Peptides Sales by Region (2027-2032)
  5. 6.3 Global Neurotransmitter Inhibitor Peptides Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neurotransmitter Inhibitor Peptides Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neurotransmitter Inhibitor Peptides Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neurotransmitter Inhibitor Peptides Sales Value by Region (2027-2032)
  9. 6.5 Global Neurotransmitter Inhibitor Peptides Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neurotransmitter Inhibitor Peptides Sales Value (2021-2032)
  12. 6.6.2 North America Neurotransmitter Inhibitor Peptides Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neurotransmitter Inhibitor Peptides Sales Value (2021-2032)
  15. 6.7.2 Europe Neurotransmitter Inhibitor Peptides Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neurotransmitter Inhibitor Peptides Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neurotransmitter Inhibitor Peptides Sales Value (2021-2032)
  21. 6.9.2 South America Neurotransmitter Inhibitor Peptides Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neurotransmitter Inhibitor Peptides Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neurotransmitter Inhibitor Peptides Sales Value Share by Country, 2025 VS 2032
7 Neurotransmitter Inhibitor Peptides Country-level Sales and Value Analysis
  1. 7.1 Global Neurotransmitter Inhibitor Peptides Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neurotransmitter Inhibitor Peptides Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neurotransmitter Inhibitor Peptides Sales by Country (2021-2032)
  4. 7.3.1 Global Neurotransmitter Inhibitor Peptides Sales by Country (2021-2026)
  5. 7.3.2 Global Neurotransmitter Inhibitor Peptides Sales by Country (2027-2032)
  6. 7.4 Global Neurotransmitter Inhibitor Peptides Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neurotransmitter Inhibitor Peptides Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neurotransmitter Inhibitor Peptides Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neurotransmitter Inhibitor Peptides Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neurotransmitter Inhibitor Peptides Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neurotransmitter Inhibitor Peptides Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Lubrizol (Lipotec)
  2. 8.1.1 Lubrizol (Lipotec) Company Information
  3. 8.1.2 Lubrizol (Lipotec) Business Overview
  4. 8.1.3 Lubrizol (Lipotec) Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Lubrizol (Lipotec) Neurotransmitter Inhibitor Peptides Product Portfolio
  6. 8.1.5 Lubrizol (Lipotec) Recent Developments
  7. 8.2 dsm-firmenich
  8. 8.2.1 dsm-firmenich Company Information
  9. 8.2.2 dsm-firmenich Business Overview
  10. 8.2.3 dsm-firmenich Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 dsm-firmenich Neurotransmitter Inhibitor Peptides Product Portfolio
  12. 8.2.5 dsm-firmenich Recent Developments
  13. 8.3 LipoTrue
  14. 8.3.1 LipoTrue Company Information
  15. 8.3.2 LipoTrue Business Overview
  16. 8.3.3 LipoTrue Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 LipoTrue Neurotransmitter Inhibitor Peptides Product Portfolio
  18. 8.3.5 LipoTrue Recent Developments
  19. 8.4 Spec-Chem Industry
  20. 8.4.1 Spec-Chem Industry Company Information
  21. 8.4.2 Spec-Chem Industry Business Overview
  22. 8.4.3 Spec-Chem Industry Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Spec-Chem Industry Neurotransmitter Inhibitor Peptides Product Portfolio
  24. 8.4.5 Spec-Chem Industry Recent Developments
  25. 8.5 GenScript
  26. 8.5.1 GenScript Company Information
  27. 8.5.2 GenScript Business Overview
  28. 8.5.3 GenScript Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GenScript Neurotransmitter Inhibitor Peptides Product Portfolio
  30. 8.5.5 GenScript Recent Developments
  31. 8.6 Active Peptide Company
  32. 8.6.1 Active Peptide Company Company Information
  33. 8.6.2 Active Peptide Company Business Overview
  34. 8.6.3 Active Peptide Company Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Active Peptide Company Neurotransmitter Inhibitor Peptides Product Portfolio
  36. 8.6.5 Active Peptide Company Recent Developments
  37. 8.7 Uniproma Chemical
  38. 8.7.1 Uniproma Chemical Company Information
  39. 8.7.2 Uniproma Chemical Business Overview
  40. 8.7.3 Uniproma Chemical Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Uniproma Chemical Neurotransmitter Inhibitor Peptides Product Portfolio
  42. 8.7.5 Uniproma Chemical Recent Developments
  43. 8.8 BOC Sciences (AAPEP)
  44. 8.8.1 BOC Sciences (AAPEP) Company Information
  45. 8.8.2 BOC Sciences (AAPEP) Business Overview
  46. 8.8.3 BOC Sciences (AAPEP) Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 BOC Sciences (AAPEP) Neurotransmitter Inhibitor Peptides Product Portfolio
  48. 8.8.5 BOC Sciences (AAPEP) Recent Developments
  49. 8.9 GfN Selco
  50. 8.9.1 GfN Selco Company Information
  51. 8.9.2 GfN Selco Business Overview
  52. 8.9.3 GfN Selco Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GfN Selco Neurotransmitter Inhibitor Peptides Product Portfolio
  54. 8.9.5 GfN Selco Recent Developments
  55. 8.10 COSROMA
  56. 8.10.1 COSROMA Company Information
  57. 8.10.2 COSROMA Business Overview
  58. 8.10.3 COSROMA Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 COSROMA Neurotransmitter Inhibitor Peptides Product Portfolio
  60. 8.10.5 COSROMA Recent Developments
  61. 8.11 Gene-Biocon
  62. 8.11.1 Gene-Biocon Company Information
  63. 8.11.2 Gene-Biocon Business Overview
  64. 8.11.3 Gene-Biocon Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Gene-Biocon Neurotransmitter Inhibitor Peptides Product Portfolio
  66. 8.11.5 Gene-Biocon Recent Developments
  67. 8.12 ChinaPeptides (QYAOBIO)
  68. 8.12.1 ChinaPeptides (QYAOBIO) Company Information
  69. 8.12.2 ChinaPeptides (QYAOBIO) Business Overview
  70. 8.12.3 ChinaPeptides (QYAOBIO) Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 ChinaPeptides (QYAOBIO) Neurotransmitter Inhibitor Peptides Product Portfolio
  72. 8.12.5 ChinaPeptides (QYAOBIO) Recent Developments
  73. 8.13 Pengting Peptide
  74. 8.13.1 Pengting Peptide Company Information
  75. 8.13.2 Pengting Peptide Business Overview
  76. 8.13.3 Pengting Peptide Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Pengting Peptide Neurotransmitter Inhibitor Peptides Product Portfolio
  78. 8.13.5 Pengting Peptide Recent Developments
  79. 8.14 RS Synthesis
  80. 8.14.1 RS Synthesis Company Information
  81. 8.14.2 RS Synthesis Business Overview
  82. 8.14.3 RS Synthesis Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 RS Synthesis Neurotransmitter Inhibitor Peptides Product Portfolio
  84. 8.14.5 RS Synthesis Recent Developments
  85. 8.15 Shenzhen JYMed Technology Co., Ltd.
  86. 8.15.1 Shenzhen JYMed Technology Co., Ltd. Company Information
  87. 8.15.2 Shenzhen JYMed Technology Co., Ltd. Business Overview
  88. 8.15.3 Shenzhen JYMed Technology Co., Ltd. Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Shenzhen JYMed Technology Co., Ltd. Neurotransmitter Inhibitor Peptides Product Portfolio
  90. 8.15.5 Shenzhen JYMed Technology Co., Ltd. Recent Developments
  91. 8.16 Nanjing Peptide Biotech
  92. 8.16.1 Nanjing Peptide Biotech Company Information
  93. 8.16.2 Nanjing Peptide Biotech Business Overview
  94. 8.16.3 Nanjing Peptide Biotech Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Nanjing Peptide Biotech Neurotransmitter Inhibitor Peptides Product Portfolio
  96. 8.16.5 Nanjing Peptide Biotech Recent Developments
  97. 8.17 AAPPTec
  98. 8.17.1 AAPPTec Company Information
  99. 8.17.2 AAPPTec Business Overview
  100. 8.17.3 AAPPTec Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 AAPPTec Neurotransmitter Inhibitor Peptides Product Portfolio
  102. 8.17.5 AAPPTec Recent Developments
  103. 8.18 Tianji Bio-pharmaceutical
  104. 8.18.1 Tianji Bio-pharmaceutical Company Information
  105. 8.18.2 Tianji Bio-pharmaceutical Business Overview
  106. 8.18.3 Tianji Bio-pharmaceutical Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Tianji Bio-pharmaceutical Neurotransmitter Inhibitor Peptides Product Portfolio
  108. 8.18.5 Tianji Bio-pharmaceutical Recent Developments
  109. 8.19 Zhejiang Peptites Biotech
  110. 8.19.1 Zhejiang Peptites Biotech Company Information
  111. 8.19.2 Zhejiang Peptites Biotech Business Overview
  112. 8.19.3 Zhejiang Peptites Biotech Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Zhejiang Peptites Biotech Neurotransmitter Inhibitor Peptides Product Portfolio
  114. 8.19.5 Zhejiang Peptites Biotech Recent Developments
  115. 8.20 Guangzhou Tongjun Pharmaceutical Technology
  116. 8.20.1 Guangzhou Tongjun Pharmaceutical Technology Company Information
  117. 8.20.2 Guangzhou Tongjun Pharmaceutical Technology Business Overview
  118. 8.20.3 Guangzhou Tongjun Pharmaceutical Technology Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Guangzhou Tongjun Pharmaceutical Technology Neurotransmitter Inhibitor Peptides Product Portfolio
  120. 8.20.5 Guangzhou Tongjun Pharmaceutical Technology Recent Developments
  121. 8.21 Hantide Biomedical Group
  122. 8.21.1 Hantide Biomedical Group Company Information
  123. 8.21.2 Hantide Biomedical Group Business Overview
  124. 8.21.3 Hantide Biomedical Group Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Hantide Biomedical Group Neurotransmitter Inhibitor Peptides Product Portfolio
  126. 8.21.5 Hantide Biomedical Group Recent Developments
  127. 8.22 Hangzhou Go Top Biotech
  128. 8.22.1 Hangzhou Go Top Biotech Company Information
  129. 8.22.2 Hangzhou Go Top Biotech Business Overview
  130. 8.22.3 Hangzhou Go Top Biotech Neurotransmitter Inhibitor Peptides Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Hangzhou Go Top Biotech Neurotransmitter Inhibitor Peptides Product Portfolio
  132. 8.22.5 Hangzhou Go Top Biotech Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neurotransmitter Inhibitor Peptides Value Chain Analysis
  2. 9.1.1 Neurotransmitter Inhibitor Peptides Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neurotransmitter Inhibitor Peptides Sales Mode & Process
  6. 9.2 Neurotransmitter Inhibitor Peptides Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neurotransmitter Inhibitor Peptides Distributors
  9. 9.2.3 Neurotransmitter Inhibitor Peptides Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst